Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Paul Diggory a Department of Elderly Care Medicine,
Mayday Hospital, Croydon CR7 7YE, b Department of Clinical
Audit, Mayday Hospital
Correspondence to: P Diggory Pdiggory{at}aol.com
Objective:
To determine whether elderly people can
learn to use the inhaler used to deliver zanamivir (Relenza Diskhaler) as effectively as the Turbohaler and to identify which aspects of
inhaler technique are most problematic.
Design:
Randomised, controlled, intervention study.
Setting:
Wards for acute elderly care in a large
district general hospital.
Participants:
73 patients who were unfamiliar with the
use of an inhaler, aged 71 to 99 (mean 83) years.
Main outcome measures:
Initial scores and changes in
scores 24 hours later using a 10 point scoring system of five aspects
of inhaler technique.
Results:
38 patients were allocated the Relenza
Diskhaler and 35 the Turbohaler. The mean total score was significantly greater in the Turbohaler than Diskhaler groups both initially (8.74 v 7.05) and after 24 hours (8.28 v 5.43). The
major difference between inhalers was in loading and priming. After
tuition 50% (19 of 38) of patients allocated the Diskhaler were unable
to load and prime the device and 65% (24 of 37) were unable to do so
24 hours later. Of those allocated the Turbohaler, two patients were
unable to load and prime the device after initial review and one after
24 hours.
Conclusion:
Most elderly people cannot use the inhaler device used to deliver the anti-influenza drug zanamivir. Treatment with this drug is unlikely to be effective in elderly people unless the
delivery system is improved.
Read all Rapid Responses